UFIS-SWE-IG
0.1.0 - ci-build
UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions
Full name: Trimonil Retard 150 mg Depottablett
- Invented Name Part: Trimonil Retard
- Strength part: 150 mg
- Pharmaceutical dose form part: Depottablett
Name usage: Swedish (Kingdom of Sweden)
Authorised dose form: Prolonged-release tablet
Legal status of supply: Medicinal product subject to medical prescription
Domain: Human use
Resource status: Current
Product classification:
Marketing Authorisation 1 of 1
Authorisation number: 12919
Region: Kingdom of Sweden
Marketing authorisation holder: Desitin Arzneimittel GmbH
Identifier:
Status: Valid (1997-05-23)
Package 1 of 1
PCID:
Description: Blister, 100 tabletter
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 10 Blister (Aluminium) (PolyVinyl Chloride)
Containing: 10 tablet
Manufactured Item
Dose form: Prolonged-release tablet
Unit of presentation: tablet
Ingredient
Role: Active
Substance: Carbamazepine
Presentation strength: 150 milligram(s) / 1 tablet
Reference strength: Carbamazepine 150 milligram(s) / 1 tablet
Administrable Product (1 of 1)
Dose form: Prolonged-release tablet
Unit of presentation:
Route of administration:
Ingredient
Role: Active
Substance: Carbamazepine
Presentation strength: 150 milligram(s) / 1 tablet
Reference strength: Carbamazepine 150 milligram(s) / 1 tablet